Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications.
about
Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative mediumCandida vaginitis: when opportunism knocks, the host respondsCandida albicans SET1 encodes a histone 3 lysine 4 methyltransferase that contributes to the pathogenesis of invasive candidiasis.Candida infections of the genitourinary tract.Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective.Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists aCandida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibilityAntifungal Susceptibility Patterns of Vulvovaginal Candida species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Uganda.Antifungal Properties of Crude Extracts, Fractions, and Purified Compounds from Bark of Curatella americana L. (Dilleniaceae) against Candida SpeciesAn update on antifungal targets and mechanisms of resistance in Candida albicans.Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013)Micafungin activity against Candida albicans with diverse azole resistance phenotypes.Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistanceVulvovaginal candidiasis in Mato Grosso, Brazil: pregnancy status, causative species and drugs testsIs it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504).Emergence of non-albicans Candida species in neonatal candidemia.A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates.Clinical characteristics of Turkish women with Candida krusei vaginitis and antifungal susceptibility of the C. krusei isolates.Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.Chronic vulvovaginal candidiasis: what we know and what we have yet to learn.Antimicrobial activity of Buchenavia tetraphylla against Candida albicans strains isolated from vaginal secretions.Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).Local Probiotic Therapy for Vaginal Candida albicans Infections.Genotyping reveals no link between Candida albicans genotype and vaginitis severity in Turkish women.Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women.Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors.Honey has an antifungal effect againstCandidaspecies
P2860
Q24630977-E0A0C476-12E8-47FC-BE3D-EE74F9731A81Q31157510-6CF6035C-021B-44C6-8731-8A924072D6A0Q33240623-736F28B4-5B51-43A5-BFBE-8CF348872439Q33825621-F6680788-E46E-4009-A30C-1D9991AC1B31Q33859133-2020A085-792E-472C-8570-E8AA4F454F51Q34186380-31C53855-2B65-4B29-80A6-E34675A0F030Q34269717-C8BBBADB-6761-496C-8EC5-1CC4D480EFC5Q35139474-4A96B87A-4C74-4BD8-BC0C-C8D8B45A90D7Q35848519-1F72F1AD-B7AE-429A-9BF3-7256256FB5A6Q35992453-21688708-F59F-4ED8-BAA1-81A8AE33A245Q36235037-FE79469E-577B-4AAE-9B39-196491AF30C2Q36743194-D8102C73-B458-47AE-A6E6-18C679B34047Q36867925-C0BC599C-BAB4-4B9A-9F90-91D280A4F76EQ36925967-C5DC5CFD-2D44-4A9A-B594-DB940DDEC134Q37159746-8069C315-E038-42EA-B6EE-AF7BEB03210AQ37280955-EF3F0ED4-316F-43B7-B414-4EE97DC3E1A9Q37283450-0CD07F9F-E0B7-4CC5-8CAE-BBAA459D847DQ37287736-8AEA4A63-0708-4FA8-A8D5-5AE3DCAA973CQ37417391-719C2856-43ED-4F3C-8CFE-9DE3D214DCF5Q37568906-6E0458FB-9672-4E74-AB0A-EEA986743704Q38045402-9ACAA0BD-D4CF-4D2A-BDBC-28A9D1451F71Q38708925-17C00797-DC54-4273-9D38-5750B1D5A61CQ39035805-A3794108-2EE3-46CF-B0B5-299BE86D7D86Q41681212-4DFDEF81-EC72-493A-8171-E8B07C85968EQ42712135-C68CCE3B-1EC6-4FF8-9B64-5E4CEE5A1BE3Q46977486-E833DD8B-8F6E-47F6-8910-A41F2C99560CQ52734706-2C9C9721-1627-4BA8-9FC9-D5EAE26253ABQ58431050-6A681C31-5E08-4D3A-9354-A962DE43BF47
P2860
Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Fluconazole susceptibility of ...... initis: clinical implications.
@ast
Fluconazole susceptibility of ...... initis: clinical implications.
@en
Fluconazole susceptibility of ...... initis: clinical implications.
@nl
type
label
Fluconazole susceptibility of ...... initis: clinical implications.
@ast
Fluconazole susceptibility of ...... initis: clinical implications.
@en
Fluconazole susceptibility of ...... initis: clinical implications.
@nl
prefLabel
Fluconazole susceptibility of ...... initis: clinical implications.
@ast
Fluconazole susceptibility of ...... initis: clinical implications.
@en
Fluconazole susceptibility of ...... initis: clinical implications.
@nl
P2093
P2860
P1476
Fluconazole susceptibility of ...... initis: clinical implications.
@en
P2093
P Nyirjesy
P2860
P356
10.1128/AAC.47.1.34-38.2003
P407
P577
2003-01-01T00:00:00Z